Sunday 11 October 2026 Export all PFE data to Excel Powerpack

Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 2.60%, EPS fell 107.8%, free cash flow grew 125.2% and total debt rose 2.26%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years; insiders bought in the last twelve months.

28.28 0.46 +1.65%
Market cap
$158.6B
P/E
37.2×
Fwd P/E
12.2×
Dividend yield
6.08%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100

Pfizer Inc. 10-K filed Feb 27, 2025

Fiscal year 2024 · Period ended Dec 31, 2024 · Filed · accepted 4:27 PM ET · Document on sec.gov · Filing index